Metformin vs MOTS-c: what the longevity science actually shows

What did @drtrevorbachmeyer actually say?

He argued that metformin is a "chemical bludgeon" that destroys mitochondria, causes vitamin B12 deficiency, raises homocysteine to neurotoxic levels, and ultimately harms the people taking it. Against that, he positioned MOTS-c, a mitochondria-derived peptide, as something that doesn't just manage metabolic disease but makes it a "physiological impossibility." Big claims. Let's look at what holds up.

He cited a "2022 meta-analysis in the Lancet" linking metformin to reduced mitochondrial DNA, a 2015 Cell Metabolism mouse study on MOTS-c and obesity, and a paper in Oncogene on MOTS-c's anti-tumor properties. He also claimed MOTS-c crosses the blood-brain barrier, upregulates BDNF, and "upgrades the operating system" of cellular metabolism through the folate-methionine cycle.

Does the science back this up?

Partially, and with some serious caveats. The metformin-mitochondria story is real but oversimplified. The MOTS-c excitement is legitimate but almost entirely preclinical. Calling MOTS-c a solution that makes diabetes "impossible" is not something any peer-reviewed paper has established in humans.

Metformin does inhibit mitochondrial complex I. That is settled biochemistry (Foretz et al., 2014, Diabetologia). It does cause B12 deficiency in a meaningful subset of users, and elevated homocysteine from B12 deficiency is associated with cognitive and vascular risk (de Jager et al., 2010, BMJ). Those are real signals worth knowing about, not invented.

MOTS-c is genuinely interesting. The 2015 Cell Metabolism paper (Lee et al.) showed that MOTS-c administration prevented obesity and insulin resistance in mice on a high-fat diet. It does activate AMPK and appears to influence one-carbon metabolism. But mice are not people, and "prevented metabolic syndrome in a mouse model" is a long walk from "immune to the disease."

What did they get wrong (or right)?

The metformin framing is where the video goes off track the most. Calling it a "disaster" ignores 60-plus years of safety data in diabetic populations and evidence that it may reduce all-cause mortality in type 2 diabetics (Campbell et al., 2017, Diabetes Care). The AMPK activation metformin triggers is actually the same pathway the creator praises MOTS-c for. He can't call AMPK activation "badass" in one molecule and a "panic response" in another without explaining why. That inconsistency is a red flag.

He got the B12-homocysteine connection right. The American Diabetes Association recommends periodic B12 monitoring for long-term metformin users precisely because this is a documented risk, not a fringe theory.

The Lancet citation about mitochondrial DNA reduction is harder to verify as described. A 2022 Lancet meta-analysis specifically showing mtDNA reduction in healthy longevity cohorts on metformin does not match any study in the published record this writer could identify. That claim needs a proper citation before it should be treated as established.

Saying MOTS-c "prevents you from getting" diabetes is not a conclusion supported by any human trial. Period. The peptide has not been tested in large-scale human longevity or diabetes prevention studies.

What should you actually know?

Metformin is not perfect, but it is one of the most studied drugs in medicine and remains a first-line treatment for type 2 diabetes for good reasons. Its risks are manageable with monitoring. MOTS-c is a genuinely novel research area, but the science is early, the human data is thin, and no regulatory body has approved it for any indication.

The comparison the video sets up, metformin as poison versus MOTS-c as upgrade, is not one the current literature supports. It is a framing built to sell excitement. If you are on metformin, ask your doctor about B12 levels. That is the actually actionable takeaway. If you are curious about MOTS-c, understand that you would be experimenting well ahead of the evidence curve. Research in this space is ongoing, including human studies on MOTS-c and insulin sensitivity, but results are not in yet.

Telehealth platforms and wellness creators have a responsibility not to frame unproven peptides as superior to established medications for serious conditions like type 2 diabetes. That framing can lead people to abandon treatments that work.